Atara Biotherapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $120.8M | $128.9M | $8.6M | $63.6M | — |
| Operating income | $35.9M | -$83.4M | -$276.0M | -$280.5M | -$340.5M |
| Operating expenses | — | — | — | $344.1M | $360.8M |
| Cash from operations | -$50.9M | -$68.7M | -$193.0M | -$270.4M | -$220.5M |
| Capital expenditure | $0 | $246,000 | $1.2M | $4.2M | $10.6M |
| Free cash flow | -$50.9M | -$69.0M | -$194.2M | -$274.6M | -$231.1M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $20.2M | $109.1M | $165.5M | $376.4M | $468.1M |
| Total liabilities | $58.7M | $206.4M | $264.7M | $249.8M | $188.5M |
Shares outstanding 9.0M · Free float 35.3%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.